AI assistant
Sending…
Monopar Therapeutics — Director's Dealing 2023
Jan 3, 2023
32883_dirs_2023-01-03_5857fa41-4fc9-4683-9819-c869a0fa7162.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2022-12-31
Reporting Person: RIOUX PATRICE (Acting Chief Medical Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-01-01 | Stock Options | $2.37 | A | 10000 | Acquired | 2031-12-31 | Common Stock (10000) | Direct |
Footnotes
F1: Stock Options vesting commenced on January 1, 2023 as follows: 833 on January 31, 2023 and each subsequent month-end thereafter.